ES2177601T3 - Ranolazina y pepeerazinas relacionadas para uso en el tratamiento de estados de choque. . - Google Patents

Ranolazina y pepeerazinas relacionadas para uso en el tratamiento de estados de choque. .

Info

Publication number
ES2177601T3
ES2177601T3 ES95119463T ES95119463T ES2177601T3 ES 2177601 T3 ES2177601 T3 ES 2177601T3 ES 95119463 T ES95119463 T ES 95119463T ES 95119463 T ES95119463 T ES 95119463T ES 2177601 T3 ES2177601 T3 ES 2177601T3
Authority
ES
Spain
Prior art keywords
treatment
pepeerazines
ranolazine
shock states
shock
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95119463T
Other languages
English (en)
Inventor
Robert J Dow
Pierre Ferrandon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syntex USA LLC
Original Assignee
Syntex USA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex USA LLC filed Critical Syntex USA LLC
Application granted granted Critical
Publication of ES2177601T3 publication Critical patent/ES2177601T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Botany (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Treatment Of Fiber Materials (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

SE PRESENTAN DERIVADOS DE LA PIPERACINA, PARTICULARMENTE RANOLACINA, QUE SON UTILES PARA EL TRATAMIENTO DE TEJIDOS QUE EXPERIMENTAN UN DAÑO FISICO Y QUIMICO, Y ESPECIFICAMENTE PARA TRATAR CONDICIONES DE SHOCK.
ES95119463T 1989-06-23 1990-06-21 Ranolazina y pepeerazinas relacionadas para uso en el tratamiento de estados de choque. . Expired - Lifetime ES2177601T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37043589A 1989-06-23 1989-06-23

Publications (1)

Publication Number Publication Date
ES2177601T3 true ES2177601T3 (es) 2002-12-16

Family

ID=23459660

Family Applications (3)

Application Number Title Priority Date Filing Date
ES95119463T Expired - Lifetime ES2177601T3 (es) 1989-06-23 1990-06-21 Ranolazina y pepeerazinas relacionadas para uso en el tratamiento de estados de choque. .
ES90111787T Expired - Lifetime ES2091211T3 (es) 1989-06-23 1990-06-21 Ranolazina y piperazinas relacionadas utilizadas en el tratamiento de tejidos que sufren una lesion fisica o quimica.
ES95119452T Expired - Lifetime ES2182863T3 (es) 1989-06-23 1990-06-21 Ranolazina y piperazinas relacionadas para proteger musculos esqueleticos.

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES90111787T Expired - Lifetime ES2091211T3 (es) 1989-06-23 1990-06-21 Ranolazina y piperazinas relacionadas utilizadas en el tratamiento de tejidos que sufren una lesion fisica o quimica.
ES95119452T Expired - Lifetime ES2182863T3 (es) 1989-06-23 1990-06-21 Ranolazina y piperazinas relacionadas para proteger musculos esqueleticos.

Country Status (13)

Country Link
US (2) US5506229A (es)
EP (3) EP0714660B1 (es)
JP (1) JP3232085B2 (es)
AT (3) ATE218344T1 (es)
AU (1) AU633589B2 (es)
CA (1) CA2019580C (es)
DE (3) DE69034000T2 (es)
DK (3) DK0719558T3 (es)
ES (3) ES2177601T3 (es)
GR (1) GR3020976T3 (es)
IE (1) IE80710B1 (es)
NZ (2) NZ234184A (es)
ZA (1) ZA904842B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69833665T2 (de) 1997-08-08 2006-11-09 Duke University Zusammensetzungen zur vereinfachung von chirurgischen verfahren
US6711436B1 (en) 1997-08-08 2004-03-23 Duke University Compositions, apparatus and methods for facilitating surgical procedures
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
HK1048250A1 (zh) 2000-02-18 2003-03-28 Cv Therapeutics, Inc. 在治疗充血性心力衰竭中使用的部分脂肪酸氧化抑制剂
US6552023B2 (en) 2000-02-22 2003-04-22 Cv Therapeutics, Inc. Aralkyl substituted piperazine compounds
US6677336B2 (en) 2000-02-22 2004-01-13 Cv Therapeutics, Inc. Substituted piperazine compounds
US6677343B2 (en) 2000-02-22 2004-01-13 Cv Therapeutics, Inc. Substituted piperazine compounds
CA2657986A1 (en) * 2000-02-22 2001-08-30 Cv Therapeutics, Inc. Substituted piperazine compounds
US6638970B2 (en) 2000-02-22 2003-10-28 Cv Therapeutics, Inc. Substituted alkylene diamine compounds
US6451798B2 (en) 2000-02-22 2002-09-17 Cv Therapeutics, Inc. Substituted alkyl piperazine derivatives
CA2420182A1 (en) * 2000-08-25 2002-03-07 Organ Recovery Systems, Inc. Methods of thrombolytic organ treatment and repair
US6573264B1 (en) * 2000-10-23 2003-06-03 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives
GB0028414D0 (en) 2000-11-22 2001-01-03 Univ Leeds Flush preservation solution
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
CA2486712C (en) * 2002-05-21 2012-01-03 Cv Therapeutics, Inc. Method of treating diabetes
JP2006510670A (ja) 2002-12-05 2006-03-30 シーブイ・セラピューティクス・インコーポレイテッド 置換ヘテロ環化合物
JP2006514066A (ja) 2003-01-03 2006-04-27 シーブイ・セラピューティクス・インコーポレイテッド 置換ヘテロ環化合物
AU2004209522A1 (en) 2003-01-17 2004-08-19 Gilead Palo Alto, Inc. Substituted heterocyclic compounds useful in the treatment of cardiovascular diseases
KR20060065586A (ko) 2003-06-23 2006-06-14 씨브이 쎄러퓨틱스, 인코포레이티드 지방산 산화 저해제로서의, 피페라진 및 피페리딘의 우레아유도체
WO2005061470A1 (en) 2003-12-18 2005-07-07 Cv Therapeutics, Inc. 1-akan-2-ol substituted piperazine and piperidine compounds
EP1789407A2 (en) * 2004-09-08 2007-05-30 Cv Therapeutics, Inc. Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
WO2006053161A1 (en) * 2004-11-09 2006-05-18 Cv Therapeutics, Inc. Use ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure
WO2006074398A2 (en) * 2005-01-06 2006-07-13 Cv Therapeutics, Inc. Sustained release pharmaceutical formulations comprising ranolazine
US20060205727A1 (en) * 2005-03-11 2006-09-14 Wayne Kaesemeyer Combination therapy for endothelial dysfunction, angina and diabetes
US20090312340A1 (en) * 2007-02-13 2009-12-17 Whedy Wang Use of ranolazine for the treatment of cardiovascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
EP2117508A1 (en) 2007-02-13 2009-11-18 CV Therapeutics Inc. Intravenous solutions comprising ranolazine
JP2010518171A (ja) * 2007-02-13 2010-05-27 ギリアード・パロ・アルト・インコーポレイテッド 非冠微小血管疾患の処置のためのラノラジンの使用
US20080248112A1 (en) * 2007-02-13 2008-10-09 Brent Blackburn Use of ranolazine for the treatment of coronary microvascular diseases
US20080233191A1 (en) * 2007-03-22 2008-09-25 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
RU2442585C2 (ru) * 2007-05-31 2012-02-20 Си Ви Терапьютикс, Инк. Способ лечения диабета
WO2008150565A2 (en) * 2007-05-31 2008-12-11 Cv Therapeutics, Inc. Ranolazine for elevated brain-type natriuretic peptide
CA2713521A1 (en) * 2008-02-06 2009-08-13 Gilead Palo Alto, Inc. Use of ranolazine for treating pain
US20090247535A1 (en) * 2008-03-26 2009-10-01 Duke University Use of ranolazine for non-cardiovascular disorders
US20100292217A1 (en) * 2009-05-14 2010-11-18 Gilead Palo Alto, Inc. Ranolazine for the treatment of cns disorders
US8901128B2 (en) 2009-05-28 2014-12-02 Lupin Limited Pharmaceutical compositions of ranolazine
EP2453893A4 (en) * 2009-07-09 2012-06-20 Ozteo Pty Ltd TREATMENT OF NON-NEURONIC AND NON-MYOCARDIAL CELL, TISSUE, ORGANIC ANGER AND RELATED PAIN THROUGH PERMANENT SODIUM CHANNEL BLOCKERS
AU2015200961B2 (en) * 2009-07-09 2017-02-16 Ozteo Pty Ltd Treatment of Non-Neuronal and Non-Cardiac Cell, Tissue and Organ Damage and Associated Pain with Persistent Sodium Current Blockers
US20120177729A1 (en) 2009-09-25 2012-07-12 Lupin Limited Sustained release composition of ranolazine
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
WO2012170676A1 (en) * 2011-06-08 2012-12-13 Sti Pharma, Llc Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
KR101476379B1 (ko) * 2011-11-30 2014-12-29 한국과학기술연구원 페녹시프로판올 유도체 및 이를 함유하는 약학적 조성물
KR101331186B1 (ko) * 2013-08-05 2013-11-22 한국과학기술연구원 페녹시프로판올 유도체 및 이를 함유하는 약학적 조성물
WO2021252951A1 (en) 2020-06-12 2021-12-16 Vanderbilt University Methods of treatment for gastrointestinal motility disorders
WO2023045740A1 (zh) * 2021-09-27 2023-03-30 天士力医药集团股份有限公司 一种治疗心肌缺血的药物组合物及其制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry

Also Published As

Publication number Publication date
DE69033967D1 (de) 2002-07-11
DE69034000T2 (de) 2003-06-05
JP3232085B2 (ja) 2001-11-26
ES2091211T3 (es) 1996-11-01
DK0719558T3 (da) 2002-10-07
ES2182863T3 (es) 2003-03-16
NZ234184A (en) 1997-01-29
AU5761890A (en) 1991-01-03
EP0407780A3 (en) 1992-01-02
IE80710B1 (en) 1998-12-16
DK0714660T3 (da) 2002-10-07
DK0407780T3 (da) 1996-09-30
US5506229A (en) 1996-04-09
EP0714660A1 (en) 1996-06-05
EP0719558B1 (en) 2002-06-05
JPH0348672A (ja) 1991-03-01
EP0407780B1 (en) 1996-09-11
GR3020976T3 (en) 1996-12-31
CA2019580C (en) 2007-03-27
ATE223218T1 (de) 2002-09-15
DE69034000D1 (de) 2002-10-10
EP0407780A2 (en) 1991-01-16
DE69033967T2 (de) 2002-12-19
CA2019580A1 (en) 1990-12-23
ATE218344T1 (de) 2002-06-15
IE902250A1 (en) 1991-01-16
NZ247044A (en) 1997-04-24
DE69028457D1 (de) 1996-10-17
ATE142497T1 (de) 1996-09-15
EP0719558A1 (en) 1996-07-03
US5906988A (en) 1999-05-25
ZA904842B (en) 1992-02-26
DE69028457T2 (de) 1997-02-20
AU633589B2 (en) 1993-02-04
IE902250L (en) 1990-12-23
EP0714660B1 (en) 2002-09-04

Similar Documents

Publication Publication Date Title
ES2177601T3 (es) Ranolazina y pepeerazinas relacionadas para uso en el tratamiento de estados de choque. .
ES2077869T3 (es) Policitraconimidas y poliitaconimidas que contienen poli(sulfuro).
DE3886548D1 (de) Riemen.
BR9205466A (pt) Composicao para fibra,artigo de fibra e fraida
AR245226A1 (es) Metodo para mejorar las propiedades del cuero curtido.
ES499935A0 (es) Procedimiento para el tratamiento de generos textiles
DE69107980D1 (de) Maschine zum vielfältigen Kodieren von Schlüsseln.
TR24204A (tr) Kumas yumusatici bilesimi.
NO903449D0 (no) Fremgangsmaate for aa behandle underjordiske formasjoner.
EA199900362A1 (ru) Новые соединения, полезные для использования в качестве нейрозащитных средств
DE69013999D1 (de) Siliconkautschukzusammensetzung zur Behandlung von Faserstrukturen.
IT8521953A0 (it) Procedimento di tintura di cuoi naturali.
ES500426A0 (es) Maquina para el planchado de tejidos,particularmente de pun-to y similares
MX9102117A (es) Metodo para el tratamiento de nematodos en terreno, empleando furfural.
IT8720424A0 (it) Procedimento e macchina per il trattamento, in particolare la tintura discontinua, di tessuti in falde.
FI873477A7 (fi) Muovilla päällystetty vuota tai kangas ja menetelmä sen valmistamiseksi.
FI903150A0 (fi) Strukturaemne foer textiltvaettmedel.
DE3881633D1 (de) Flammbehandelte monofilamente.
ES2066096T3 (es) 4-bencil-5-fenil-2,4-dihidro-3h-1,2,4-triazol-3-onas y su uso como anticonvulsivos.
IT8420682A0 (it) Procedimento per il trattamento di articoli di maglieria.
DE69006562D1 (de) Wasser-in-Öl Emulsion.
DE3887970D1 (de) Zusammensetzung zum Behandeln von Textilien.
ES2053942T3 (es) Empleo de aductos de oxido de 1,2-butileno en compuestos organicos h-azidas como lubricantes y lubricantes que contienen estos aductos.
ES491921A0 (es) Procedimiento para preparar agentes para el tratamiento de fibras queratinicas
DE69003366D1 (de) Maschine zum Supfinieren von Wellen, insbesondere Nockenwellen.